Clopidogrel pretreatment may reduce early acquired thrombocytopenia after transcatheter aortic valve replacement (TAVR).

KE Ashley, WB Hillegass - … : Official Journal of the Society for …, 2019 - europepmc.org
KE Ashley, WB Hillegass
Catheterization and Cardiovascular Interventions: Official Journal of …, 2019europepmc.org
Transcatheter aortic valve replacement (TAVR) causes early acquired thrombocytopenia on
postoperative Days 1 and 2 in 30-50% of patients. While usually transient and rarely severe,
early acquired thrombocytopenia is strongly associated with 30-day and 1-year post-TAVR
outcomes, including mortality. Observation from a prospective registry suggests pretreatment
with the P2Y 12 receptor inhibitor clopidogrel before TAVR reduces the frequency and
magnitude of early acquired thrombocytopenia. If a protective effect of clopidogrel …
Transcatheter aortic valve replacement (TAVR) causes early acquired thrombocytopenia on postoperative Days 1 and 2 in 30-50% of patients. While usually transient and rarely severe, early acquired thrombocytopenia is strongly associated with 30-day and 1-year post-TAVR outcomes, including mortality. Observation from a prospective registry suggests pretreatment with the P2Y 12 receptor inhibitor clopidogrel before TAVR reduces the frequency and magnitude of early acquired thrombocytopenia. If a protective effect of clopidogrel pretreatment on early thrombocytopenia can be confirmed, then further study to determine if this translates into improved TAVR outcomes is warranted.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果